Duke doctor named new chair of NCCN board of directors

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 4
Volume 19
Issue 4

Thomas A. D’Amico, MD, has been elected chair of the board of directors of the National Comprehensive Cancer Network.

Thomas A. D'Amico, MD, has been elected chair of the board of directors of the National Comprehensive Cancer Network.

Dr. D'Amico is director of clinical oncology, program director of thoracic surgery, and professor in the department of surgery at Duke Comprehensive Cancer Center at Duke University in Durham, N.C.

His areas of expertise include the molecular biology of lung cancer, esophageal cancer, and also thoracic surgery. He is a member of several NCCN committees, and serves on the NCCN guidelines panel for esophageal/gastric cancers as well as on the panel for non-small-cell lung cancer.

Dr. D'Amico was previously vice-chair of the NCCN board and succeeds Al B. Benson III, MD, as chair.

Related Videos
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD
video 8 - "Treatment Landscape for NSCLC With EGFR Exon 20 Insertion Mutations"
Video 7 - "Second-Line Treatment of Patients With EGFR-Mutated NSCLC"
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer
A panel of 5 experts on liver cancer